Bladder cancer is diagnosed in 550K patients and causes 200K deaths per year, making it the ninth most common cancer worldwide. Non-muscle invasive bladder cancer (NMIBC) accounts for ~75% of bladder cancers at diagnosis and has a 60-70% risk of recurrence and a 20% risk of progression within five years, making BC the most expensive cancer to treat ($187,000 lifetime cost per patient).

Drug delivery is particularly challenging in NMIBC due to the low permeability of the urothelium and the continuous filling of urine and subsequent washout of the bladder.

NBT-101 program will allow the pharmaceutical industry access to safer and more effective therapies to combat NMIBC.

In collaboration with Toni Vilaseca (Hospital Clinic).